Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Budesonide  COVID-19 treatment studies for Budesonide  C19 studies: Budesonide  Budesonide   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Budesonide for COVID-19: real-time meta analysis of 9 studies
Covid Analysis, December 2022
https://c19early.org/umeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ramakrish.. (RCT) 82% 0.18 [0.04-0.79] hosp./ER 2/73 11/73 Improvement, RR [CI] Treatment Control Ramakrish.. (RCT) 90% 0.10 [0.01-0.75] hosp./ER 1/70 10/69 Ramakrish.. (RCT) 67% 0.33 [0.15-0.72] no recov. 7/70 21/69 Ramlall (ICU) 71% 0.29 [0.11-0.78] death 33 (n) 915 (n) Intubated patients Yu (RCT) 39% 0.61 [0.22-1.67] death 6/787 10/799 Yu (RCT) 6% 0.94 [0.44-1.98] ventilation 13/776 14/784 Yu (RCT) 52% 0.48 [0.23-1.01] ICU 10/771 21/779 Yu (RCT) 25% 0.75 [0.55-1.03] death/hosp. 72/787 116/1,069 Yu (RCT) 17% 0.83 [0.74-0.93] recov. time 787 (n) 1,069 (n) Al Sulaiman (ICU) 32% 0.68 [0.41-1.13] death 30/64 31/64 ICU patients MP 80%​1 Al Sulaiman (ICU) 47% 0.53 [0.31-0.93] death 25/65 29/65 ICU patients MP 80%​1 Alsultan (RCT) -7% 1.07 [0.42-2.71] death 5/14 7/21 Agustí (RCT) -23% 1.23 [0.08-19.0] death 1/40 1/49 Agustí (RCT) 39% 0.61 [0.12-3.17] progression 2/40 4/49 Lee 33% 0.67 [0.42-1.08] cases 19/1,674 95/5,345 Monserrat .. (PSM) 49% 0.51 [0.28-0.90] death n/a n/a Loucera 22% 0.78 [0.65-0.92] death 1,047 (n) 14,921 (n) Budesonide COVID-19 outcomes c19early.org/u Dec 2022 1 MP: multiple medications, percentage budesonide shown Favors budesonide Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit